Keywords: Valeant Pharmaceuticals, Obagi Medical Products, M&A, Prescription skin-care
Valeant to acquire Obagi Medical for around $344 million
Article | 20 March 2013
Canada-based Valeant Pharmaceuticals International (TSX: VRX) is on the acquisition trail again, announcing a definitive agreement to buy all the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
